Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29089994 | 0.98 | TSHR (0.34) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL378129 | 0.93 | TSHR (0.34) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL12499298 | 0.91 | ALDH1A1 (0.35) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL21296526 | 0.86 | — | — | |
| SCHEMBL1355575 | 0.79 | TSHR (0.41) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL12155643 | 0.79 | TSHR (0.36) | TSHRNFKB1CYP2C19KDM5AKDM4C | |
| SCHEMBL27861360 | 0.77 | TSHR (0.35) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL27844146 | 0.77 | CNR2 (0.36) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL22964983 | 0.77 | DPP4 (0.35) | TSHRNFKB1CYP2C19DPP4KDM5A | |
| SCHEMBL11040604 | 0.77 | FFAR3 (0.34) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929345-A | Substituted pyrazole compounds as TOLL receptor inhibitors | 百时美施贵宝公司 | 2022-08-19 | — | — | CN | claimed |
| EP-3353155-A1 | PYRIDYL OR PYRAZINYL COMPOUNDS CARRYING A METHYL-BOUND ALPHA-AMINO ACID AMIDE GROUP | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-01 | — | — | EP | claimed |
| WO-2017050807-A1 | PYRIDYL OR PYRAZINYL COMPOUNDS CARRYING A METHYL-BOUND ALPHA-AMINO ACID AMIDE GROUP | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-30 | — | — | WO | claimed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | claimed |
| JP-4377942-B2 | — | — | 2009-12-02 | — | — | JP | claimed |
| JP-2008531599-A | — | — | 2008-08-14 | — | — | JP | claimed |
| EP-1856057-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | Serenex, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006091963-A1 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | claimed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | claimed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | claimed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | claimed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | claimed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | claimed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-03-16 | — | — | US | disclosed |
| EP-3917616-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | TSHR 3339/4885NFKB1 2889/4885CYP2C19 4163/4885 |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | TSHR 4021/4885NFKB1 1314/4885CYP2C19 1381/4885 |
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | TSHR 1226/4885NFKB1 1350/4885CYP2C19 4217/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | TSHR 3357/4885NFKB1 2866/4885CYP2C19 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.